<DOC>
	<DOCNO>NCT01511978</DOCNO>
	<brief_summary>Hypothesis : 3,4-DAP improves Lambert-Eaton Myasthenic Syndrome ( LEMS ) -related weakness .</brief_summary>
	<brief_title>Effectiveness 3,4-Diaminopyridine Lambert-Eaton Myasthenic Syndrome</brief_title>
	<detailed_description>The objective study confirm safety test efficacy 3,4-DAP treatment LEMS-related weakness . This phase 2 randomize double-blind placebo-controlled withdrawal study subject know clinically active LEMS chronic stable dose compassionate distribution Jacobus 3,4-DAP provide FDA-approved individual investigator-held INDs .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Age 18 2 . Ambulatory take 3,4DAP , i.e . patient perform time go ( TUG ) , either without assistive device 3 . Established diagnosis LEMS , documentation provide 4 . Continuous use JPC 3,4DAP least 3 month 5 . Minimum 3 dos per day single dose less 10 mg 3,4DAP 6 . The patient need wait 15 30 minute experience unequivocal improvement LEMSinduced dysfunction take first dose 3,4DAP morning [ patient remain bed past point choice may still eligible ] 7 . Stable regimen LEMSrelated treatment least 3 month 8 . Stable daily regimen medication ( prescription overthecounter ) minimum 1 month 9 . Willing chance taper 3,4DAP 10 . Fluency English 11 . If applicable , agree use birth control heterosexual intercourse least 2 week completion study 12 . A sign inform consent study subject 1 . Last monoclonal antibody treatment ( e.g . rituximab ) less 6 month ago ( i.e. , recent treatment exclusion ) 2 . Clinically significant poorly control condition opinion study personnel might pose unacceptable risk patient enter study 3 . Respiratory failure require intubation 3,4DAP precipitate event medication 4 . Use investigational drug 3,4DAP within last 30 day 5 . Pregnant lactate 6 . Current use aminopyridines ( e.g.4AP ) guanidine 7 . Does display sufficiently large response 3,4DAP baseline observation period CRU detect decline withdrawal 3,4DAP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lambert-Eaton</keyword>
	<keyword>Eaton-Lambert</keyword>
	<keyword>myasthenia</keyword>
	<keyword>myasthenic</keyword>
	<keyword>LEMS</keyword>
	<keyword>LES</keyword>
	<keyword>DAP</keyword>
	<keyword>diaminopyridine</keyword>
	<keyword>3,4-diaminopyridine</keyword>
	<keyword>3,4-DAP</keyword>
</DOC>